Acutaas Chemicals Limited share price
NSE: ACUTAAS · ISIN INE00FF01025
Key numbers
- Market cap
- ₹ 26,792 Cr
- Current price
- ₹ 3,272.50
- 52-week high / low
- ₹ 3,740 / 1,302
- Stock P/E
- 69.7
- Book value
- ₹ 201.9
- Dividend yield
- 0.08%
- ROCE
- 32.2%
- ROE
- 24.0%
- Debt to equity
- 0.02
- Sales growth (3 yrs)
- 29.4%
- Profit growth (3 yrs)
- 62.3%
- 1-year return
- 125.8%
About Acutaas Chemicals Limited
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients, as well as new chemical entities. It also provides specialty chemicals, including photoresist chemicals for semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 302 | 207 | 393 | 422 | 330 |
| Operating profit | 85 | 51 | 151 | 184 | 113 |
| Net profit | 62 | 44 | 108 | 132 | 74 |
| EPS (₹) | - | 5.41 | 13.19 | - | 9.07 |
Concall summary (2026-07-28)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- To conclude, we have started the new financial year on a strong note and I remain confident of delivering 25% revenue growth for the full year with stable margins.
- We are still very much confident to deliver 25% growth rate for the revenue as confirmed by the CMD also.
Growth & demand
- We delivered strong revenue of INR329.7 crores, which is growth of 59.1% Y-o-Y.
- Starting with Advanced Pharmaceutical Intermediates segment, this segment delivered robust performance with revenue of INR292.7 crores in Q1 FY '27, reflecting a strong year-on-year growth of 76.5%.
Margins & costs
- EBITDA for the quarter was INR113.1 crores, which represents more than twofold increase compared to the EBITDA of the same period last year.
- EBITDA margin were at 34.3%, up 973 basis points Y-o-Y.
Capex & expansion
- Now turning to the capital expenditures. capex for Q1 FY '27 stood at INR56 crores, out of which INR15 crores were at the Indichem site, remaining INR41 crores in ACL site, which is primarily diverted towards the battery chemical project at the Jhaghadia site.
- As mentioned on our previous earnings call, we will incur additional capex for a new R&D center and for the acquisition of land for further capacity expansion, we will update the market once these projects are finalized.
Balance sheet & cash
- Net cash and cash equivalents were around INR314 crores as on 30th June 2026.
- Our working capital for the quarter stands at 99 days versus 91 days in Q4 FY '26.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.